Cancer Anorexia Market Insight, Epidemiology, And Market Forecast - 2036 Report Reveals Why A ~$500M Market Still Has No Approved Therapy In The US Or Europe As Artelo's ART27.13 Nears Phase II Readout
Dublin, Oct. 07, 2026 (GLOBE NEWSWIRE) -- "Cancer Anorexia - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering.
Research and Markets has published Cancer Anorexia - Market Insight, Epidemiology, and Market Forecast - 2036, a 200-page report published in July 2026. The report puts the cancer anorexia market across the seven major markets (7MM) at about $500 million in 2025. It provides historical and forecast analysis for 2022-2036 across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
Key Facts
- 7MM market size (2025): about $500 million US incident cases (2025): about 285,600, the highest in the 7MM Leading cancer type: lung cancer accounts for the highest incidence of cancer anorexia in the US EU4 and UK: Germany has the most incident cases and Spain the fewest Disease burden: Cancer Anorexia and Cachexia Syndrome (CACS) affects more than 60% of advanced-stage cancer patients Approved therapies: none authorised for cancer anorexia in the US, Europe, or Japan
A Significant Unmet Need
Cancer anorexia develops frequently in patients with advanced cancers, including:
- colorectal cancer lung cancer pancreatic cancer head and neck cancer gastro-esophageal cancer liver cancer
The 2020 ASCO guidelines recommend no specific drug treatment as standard of care. The only approved therapy for the related condition of cancer cachexia is anamorelin (ADLUMIZ), from Helsinn Healthcare and Ono Pharmaceutical, and it is available only in Japan.
The report also finds that cancer anorexia is significantly underdiagnosed, because routine oncology practice lacks standardised screening protocols and clear diagnostic criteria.
Current Treatment Landscape
Management today is mainly symptomatic. It relies on appetite stimulants such as megestrol acetate, short-term corticosteroids such as dexamethasone, nutritional support, and physical activity. The report notes that these approaches do not address the underlying metabolic and inflammatory drivers of the condition.
Market Drivers
The report identifies three factors driving the market:
- a shift toward mechanism-based therapies that target inflammatory cytokines and metabolic pathways an ageing population that is more vulnerable to cancer and muscle wasting growing emphasis on supportive and palliative care
Pipeline Analysis
The pipeline remains limited and is driven mainly by smaller biotech companies. ART27.13 from Artelo Biosciences is a once-daily oral dual cannabinoid receptor agonist targeting CB1 and CB2. It was originally developed by AstraZeneca and has been studied in seven clinical trials involving more than 280 participants.
In November 2025, Artelo reported interim Phase II Cancer Appetite Recovery Study (CAReS) results. Patients receiving the top dose gained an average of 6.4% in weight. Artelo expects top-line data in the second half of 2026 or the first half of 2027.
Unmet Needs
The report highlights four gaps in current care:
- a lack of highly effective disease-modifying therapies underdiagnosis and undertreatment the absence of globally approved, standardised treatment guidelines heterogeneous patient populations
KOL Insights
Analysts consulted more than 15 key opinion leaders at centres including the Duke Molecular Physiology Institute, Hospital Universitario Fundación Alcorcón, and Nippon Medical School.
Report Scope
The report covers:
- disease background and diagnosis treatment algorithms epidemiology forecasts emerging therapy profiles drug uptake and peak patient share analysis market size by therapy and country pricing and analogue assessment market access and reimbursement SWOT and conjoint analysis
A selection of companies mentioned in this report includes, but is not limited to:
- Artelo Biosciences
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment